Navigation Links
Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
Date:3/30/2009

LA JOLLA, Calif., March 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the United States District Court of the Southern District of New York dismissed proceedings filed in February 2005 by former stockholders of Axonyx Inc. ("Axonyx") against Axonyx and several of Axonyx's former directors and officers. TorreyPines acquired Axonyx Inc. in 2006. The plaintiffs alleged that the defendants made misleading statements related to Phase III clinical trials of Axonyx's drug candidate, phenserine. The complaint was dismissed in its entirety. In January 2009 a related outstanding derivative action against Axonyx was discontinued by the New York Supreme Court.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:                                Investor contact:
    Paul Schneider                                  Rhonda Chiger
    TorreyPines Therapeutics, Inc.                  Rx Communications Group
    858-623-5665 x 125                              (917) 322-2569
    pschneider@TPTXinc.com                          rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
2. Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders
3. Kyphon Stockholders Approve Merger with Medtronic
4. Paramount Stockholders Approve Acquisition of Chem Rx
5. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
10. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
11. Special Stockholders Meeting to Elect Directors Set for March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... 8, 2016 AskLinkerReports.com has published a ... Global Amyloglucosidase Industry 2016 Market Research Report. From a basic ... chain overview are all covered in the report. This report ... return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
(Date:12/8/2016)... , December 8, 2016 ... Unternehmen für Molekulargenetik, erweitert seine Palette an anpassbaren ... NGS Custom FH Panels, das ein schnelles und ... ermöglicht. Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen ... (CNV) mit einem einzigen kleinen Panel und ermöglicht ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):